Cell toxicity may result in organ dysfunction and cause severe health problem. Recent
studies revealed many toxicants may induced the over production of Nitric oxide, reactive …

Although transplantation procedures have been developed for patients with end-stage
hepatic insufficiency or other diseases, allograft rejection still threatens patient health and …

Solid organ transplants are rarely performed in both adult and pediatric patients with primary
mitochondrial disease. Poor outcomes have been described in case reports and small case …

Calcineurin inhibitors (CNIs) frequently induce neurological complications early after
orthotopic liver transplantation (OLT). We hypothesize that longterm CNI therapy after OLT …

Background About 50% of the patients 5–7 years after kidney transplantation show
impairment of memory, attention and executive function. Tacrolimus frequently induces …

Background New-onset diabetes after transplantation (NODAT) is a significant co-morbidity
following kidney transplantation. Lower post-transplant serum magnesium levels have been …

Background In the first weeks after liver transplantation about 30% of the patients develop a
posttransplant encephalopathy. A posttransplant encephalopathy comprises metabolic-toxic …

Abstract Tacrolimus (FK506), an immunophilin ligand, has been widely shown to be
neuroprotective in a posttraumatic period. The nuclear factor of activated T cells (NFATc1) …

Abstract Background and aims Tacrolimus (Tac) is an immunosuppressive drug widely used
to avoid organ rejection. New-onset diabetes after transplantation (NODAT) is a major …

Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used globally to prevent
rejection after organ transplantation. Although it significantly improves outcomes for solid …